2,552
Views
19
CrossRef citations to date
0
Altmetric
Research Paper

Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies

, , , , , , , & show all
Pages 72-80 | Received 24 Jan 2019, Accepted 01 Sep 2019, Published online: 29 Sep 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Karolina Pierzynowska, Joanna Morcinek-Orłowska, Lidia Gaffke, Weronika Jaroszewicz, Piotr M. Skowron & Grzegorz Węgrzyn. (2023) Applications of the phage display technology in molecular biology, biotechnology and medicine. Critical Reviews in Microbiology 0:0, pages 1-41.
Read now

Articles from other publishers (18)

Kim Anh Giang, Thorstein Boxaspen, Yumei Diao, Johan Nilvebrant, Mizuha Kosugi-Kanaya, Minoru Kanaya, Silje Zandstra Krokeide, Fredrik Lehmann, Stefan Svensson Gelius, Karl-Johan Malmberg & Per-Åke Nygren. (2023) Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells. New Biotechnology 77, pages 139-148.
Crossref
Nidiane Dantas Reis Prado, Nairo Brilhante-Da-Silva, Rosa Maria Oliveira Sousa, Michelle Suelen da Silva Morais, Sibele Andrade Roberto, Marcos Barros Luiz, Livia Coelho de Assis, Anna Carolina M. Marinho, Luiz Felipe Lemes de Araujo, Rafael de Souza Pontes, Rodrigo Guerino Stabeli, Carla Freire Celedonio Fernandes & Soraya dos Santos Pereira. (2023) Single-domain antibodies applied as antiviral immunotherapeutics. Journal of Virological Methods 320, pages 114787.
Crossref
Min-ling Liu, Zi-jian Chen, Xiao-qing Huang, Hong Wang, Jin-li Zhao, Yu-dong Shen, Lin Luo, Xiao-wei Wen, Bruce Hammock & Zhen-lin Xu. (2023) A bispecific nanobody with high sensitivity/efficiency for simultaneous determination of carbaryl and its metabolite 1-naphthol in the soil and rice samples. Environmental Pollution 335, pages 122265.
Crossref
Yangyang Li, Siqi Xie, Minhua Chen, Hao Li, Yehai Wang, Yan Fan, Kang An, Yu Wu & Weihua Xiao. (2023) Development of an antibody-ligand fusion protein scFvCD16A-sc4-1BBL in Komagataella phaffii with stimulatory activity for Natural Killer cells. Microbial Cell Factories 22:1.
Crossref
Amirhosein Maali, Monireh Gholizadeh, Saba Feghhi-Najafabadi, Ahmad Noei, Seyedeh Sheila Seyed-Motahari, Shafieeh Mansoori & Zahra Sharifzadeh. (2023) Nanobodies in cell-mediated immunotherapy: On the road to fight cancer. Frontiers in Immunology 14.
Crossref
Yumei Li, Lingjun Wu, Yueying Liu, Siwen Ma, Biyi Huang, Xianjing Feng & Hui Wang. (2022) A novel multifunctional anti-PD-L1-CD16a-IL15 induces potent cancer cell killing in PD-L1-positive tumour cells. Translational Oncology 21, pages 101424.
Crossref
Mehdi Arbabi-Ghahroudi. (2022) Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments. International Journal of Molecular Sciences 23:9, pages 5009.
Crossref
Jiewen Wang, Guangbo Kang, Haibin Yuan, Xiaocang Cao, He Huang & Ario de Marco. (2022) Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment. Frontiers in Immunology 12.
Crossref
Yueyuan Yin, Fei Yan, Ruimin Zhou, Mingchen Li, Jinyi Ma, Zhe Liu & Zhenyi Ma. (2021) Single-domain antibody screening by is PLA-seq . Life Science Alliance 5:1, pages e202101115.
Crossref
Elizabeth A. Lampros, Paul G. Kremer, Jesús S. Aguilar Díaz de León, Elijah T. Roberts, Maria Carolina Rodriguez Benavente, I. Jonathan Amster & Adam W. Barb. (2022) The antibody-binding Fc gamma receptor IIIa / CD16a is N-glycosylated with high occupancy at all five sites. Current Research in Immunology 3, pages 128-135.
Crossref
Yumei Li, Yanwen Zhu, Shu Feng, Yuji Ishida, Tsu-Pei Chiu, Takeshi Saito, Sean Wang, David K. Ann & Jing-hsiung James Ou. (2022) Macrophages activated by hepatitis B virus have distinct metabolic profiles and suppress the virus via IL-1β to downregulate PPARα and FOXO3. Cell Reports 38:4, pages 110284.
Crossref
Ondřej Vaněk, Barbora Kalousková, Celeste Abreu, Shiva Nejadebrahim & Ondřej Skořepa. 2022. Immunotherapeutics. Immunotherapeutics 91 133 .
Henk van Faassen, Dong-Hyeon Jo, Shannon Ryan, Michael J. Lowden, Shalini Raphael, C. Roger MacKenzie, Seung-Hwan Lee, Greg Hussack & Kevin A. Henry. (2021) Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC. Molecular Pharmaceutics 18:6, pages 2375-2384.
Crossref
Zhimin Xu, Chuangnan Qiu, Biyan Wen, Shuang Wang, Linfeng Zhu, Lin Zhao & Huangjin Li. (2021) A bispecific nanobody targeting the dimerization interface of epidermal growth factor receptor: Evidence for tumor suppressive actions in vitro and in vivo. Biochemical and Biophysical Research Communications 548, pages 78-83.
Crossref
Anthony Brouillard, Nilesh Deshpande & Ashish A. Kulkarni. (2021) Engineered Multifunctional Nano‐ and Biological Materials for Cancer Immunotherapy. Advanced Healthcare Materials 10:6.
Crossref
Zi-Wen Han, Zhi-Wu Lyv, Bin Cui, Ying-Ying Wang, Jun-Ting Cheng, Ying Zhang, Wen-Qi Cai, Yang Zhou, Zhao-Wu Ma, Xian-Wang Wang, Xiao-Chun Peng, Shu-Zhong Cui, Ying Xiang, Mo Yang & Hong-Wu Xin. (2020) The old CEACAMs find their new role in tumor immunotherapy. Investigational New Drugs 38:6, pages 1888-1898.
Crossref
Ario de Marco. (2020) Recombinant expression of nanobodies and nanobody-derived immunoreagents. Protein Expression and Purification 172, pages 105645.
Crossref
Emily Y. Yang & Khalid Shah. (2020) Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics. Frontiers in Oncology 10.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.